PetCure Oncology Changes the Landscape for Pets with Prostate Cancer

Revolutionary stereotactic radiosurgery treatment offers new hope for
survival and quality of life

CHICAGO–(BUSINESS WIRE)–Prostate cancer is among the most common cancers in American men, but it
can be just as devastating for male dogs, accounting for as much as one
percent of all reported malignancies. As the medical community focuses
on the devastating disease during Prostate
Cancer Awareness Month
, PetCure
Oncology
is taking the lead in providing a revolutionary treatment
called Stereotactic
Radiosurgery
(SRS) that offers new hope for pets diagnosed with
cancer.

SRS is an advanced form of radiation therapy that is now available to
the veterinary community through PetCure Oncology’s rapidly growing
national network of treatment centers. Already proven successful in
human medicine, SRS offers tremendous benefits by delivering high doses
of radiation with sub-millimeter precision in a non-invasive,
non-surgical manner. In addition to treating the patient with the intent
to cure, SRS requires only 1-5 treatment sessions as opposed to 15-30
with conventional radiation therapy, while minimizing both the risk and
the side effects commonly associated with conventional treatment.

Pets diagnosed with prostate cancer have historically experienced an
average survival rate of just weeks to months. For afflicted pets and
their families, this new treatment option may mean the difference
between life and death.

“Prostate cancer can develop in neutered or intact male dogs of any age,
but it typically occurs in older dogs, usually around 10 years of age,”
explains Neal
Mauldin, DVM, DACVIM (Internal Medicine and Oncology), DACVR (RO),
a
triple board-certified veterinary specialist and chief medical officer
at PetCure Oncology. “And while the disease can occur in any breed, it
more commonly affects larger breeds, which generally have a shorter life
expectancy than small dogs to begin with.”

Dr. Mauldin also notes that most prostate tumors in dogs are locally
advanced or have metastasized by the time they are diagnosed, making
early detection just as important as in humans. Early symptoms of the
disease to be aware of include bloody urine, straining to urinate, and
increased urination of small amounts. Weight loss and ribbon shaped
stool often appear much later in the disease process, usually after
there is systemic spread of the cancer. Since the early signs of
prostate cancer mimic those of lower urinary tract infection, it can
make early diagnosis problematic because many dogs will be treated with
repeated courses of antibiotics rather than getting a timely ultrasound
or other imaging. Pet owners who notice any of these symptoms in their
dog should ask their family veterinarian about a referral to PetCure
Oncology for a consultation with a board-certified veterinary cancer
specialist.

Cancer accounts for nearly 50 percent of all disease-related pet deaths
and is the leading cause of death in older dogs and cats. PetCure
Oncology is revolutionizing the treatment of cancer in companion animals
by establishing veterinary radiosurgery centers across the country.
Centers in Phoenix,
Cincinnati,
and Clifton,
NJ
are operational. Locations in Wisconsin and Illinois are slated
to open in the next few months, with many more in various stages of
development across the country.

To learn more or obtain a referral to PetCure Oncology, visit PetCureOncology.com
or call (773) 850-3400.

Contacts

PetCure Oncology
JoAnn Stewart, RVT, CVPM
Chief Operating
Officer
M: 847-275-8600
jstewart@PetCureOncology.com